P2X 7 receptor antagonists and their use

Details P2X 7 receptor antagonists and their use P2X 7 receptor antagonists and their use

2004-06-01

2008-08-05

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S139000, C546S152000

Reexamination Certificate

active

07408065

ABSTRACT:
The invention provides compounds of formula (IA), processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.

REFERENCES:
patent: 3464998 (1969-09-01), Krimmel
patent: 3471491 (1969-10-01), Venkatachala et al.
patent: 4751292 (1988-06-01), Fox
patent: 5804588 (1998-09-01), Dyke et al.
patent: 6949539 (2005-09-01), Alcaraz et al.
patent: 7129246 (2006-10-01), Alcaraz et al.
patent: 2001/0003121 (2001-06-01), Baxter et al.
patent: 2004/0236109 (2004-11-01), Van Straten et al.
patent: 650919 (1964-07-01), None
patent: 1943404 (1970-12-01), None
patent: 0002065 (1979-05-01), None
patent: 0501656 (1992-09-01), None
patent: 0867436 (1998-09-01), None
patent: 0940391 (1999-09-01), None
patent: WO 95/04720 (1995-02-01), None
patent: WO 97/19926 (1997-06-01), None
patent: WO 99/26927 (1999-06-01), None
patent: WO 99/29660 (1999-06-01), None
patent: WO 99/29661 (1999-06-01), None
patent: WO 00/61569 (2000-10-01), None
patent: WO 00/73283 (2000-12-01), None
patent: WO/2001/037826 (2001-05-01), None
patent: WO 01/94338 (2001-12-01), None
patent: WO/03/080579 (2003-03-01), None
patent: WO 03/042190 (2003-05-01), None
patent: WO03045313 (2003-06-01), None
patent: WO 03/080579 (2003-10-01), None
patent: WO 03080579 (2003-10-01), None
patent: WO 2004/106305 (2004-12-01), None
patent: WO 2005/009968 (2005-02-01), None
patent: WO 2006/059945 (2006-06-01), None
STN International, file CHEMCATS, Accession No. 2002:1977776, Jul. 9, 2002, BAS 1098675, “Cyclopropanecarboxamide, N-(2-methyl-5-quinolinyl)-”, CAS Registry No. 333432-34-1.
STN International, file CHEMCATS, Accession No. Jan. 11, 2001, Cyclopropanecarboxamide, N-(2,6-dimethyl-5-quinolinyl)-(9CI)(CA Index Name), CAS Registry No. 313479-89-9
Modena et al., “Plant Growth Regulating Activities of 2-[2-(Arylamino)-2-oxoethyl]benzoic acids”,II Farmaco48(4):567-572 (1993).
Sharma et al., “Studies on Fused β-Lactams: Synthesis & Antibacterial Activity of Some Pyridyl/Quinolyl-2-azetidinones”,Indian Journal of Chemistry27B:494-497 (1988).
Alcaraz et al., Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155.
Alcaraz et al., “Novel P2X7 Receptor Antagonists”Bioorganic and Medicinal Chemistry Letters, 13:4043-4046 (2003).
Baxter et al., “Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists,”Bioorganic and Medicinal Chemistry Letters, 13:4047-4050 (2003).
Bourrie et al., “SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties,”Eur. J. of Pharm., 456:123-131 (2002).
Costakis et al., “Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles”,Journal of Medicinal Chemistry14(12):1222-1223 (1971).
Ferrari et al., “Extracellular ATP Triggers IL-1β Release by Activating the Purinergic P2Z Receptor of Human Macrophages”,J. Immunol. 159:1451-1458 (1997).
Ferrari et al., “Purinergic Modulation of Interleukin-1β Release from Microglial Cells Stimulated with Bacterial Endotoxin”,J. Exp. Med. 185(3):579-582 (1997).
Henderson et al., “Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist”,Cytokine3(3):246-249 (1991).
Ho et al., “Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[ij]quinoline as a VLA-4 Antagonist”,J. Org. Chem. 65:6743-6748, p. 6745, scheme 5, (27) (2000).
Kadota et al., “Significance of IL-1β and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)”,Clin Exp. Immunol. 103:461-466 (1996).
Khurana et al., “Clinical aspects of rheumatoid arthritis”, Pathophysiology, vol. 12, Issue 3, Abstract (2005).
Kirkham, “Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis”,Annals of the Rheumatic Diseases, 50:395-400 (1991).
Li et al., “Should atherosclerosis be considered a cancer of the vascular wall?”Medical Hypotheses, 64:694-698 (2005).
Mackenzie et al., “Could rheumatoid arthritis have an infectious aetiology?” Drug Discovery Today: Disease Mechanism, vol. 2, Issue 3, Abstract (2005).
Otterness et al., “Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions”, Agent Act 39 (Suppl):109-120 (1993).
Richards et al., “Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy,” Eur. J. of Medic. Chem., 41:950-969 (2006).
Sakito et al., “Interleukin 1β, Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy”,Respiration63:42-48 (1996).
STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, Apr. 14, 2002.
STN International, File REGISTRY, see RN 445032-09-7, Aug. 30, 2002.
STN International, File CHEMCATS, Accession No. 2001:48444, May 14, 2001, NS18552, 2-Quinolinecarboxamide, N-(tricycle[3.3.1.13,7]dec-1-ylmethyl), CAS Registry No. 313688-07-2.
STN International, File REGISTRY, see RN 401622-10-4, Mar., 24, 2002.
van den Berg, Lessons from animal models of osteoarthritis,Curr. Opin. Rheumatol, 13(5): 452-6 (2001).
Yu et al., “Inhibition of IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract ofTripterygium wilfordiiHook”,Gen. Pharmac. 25(6):1115-1122 (1994).
Ayral-Kaloustian, Semiramis et al., “Preparation of 3-Hydroxycyclohexaneacetonitriles”,Journal of Organic Chemistry, vol. 46, No. 24, (1981), pp. 4880-4885.
Biggs, D. F. et al., “Snythesis and Pharmacological Evaluation of Some ββ-Disubstituted Analogs of Acetylcholine”,Journal of Medicinal Chemistry, vol. 15, No. 6, (1972), pp. 642-646.
Fülöp, Ferenc et al., “A Versatile Method For The Synthesis ofcis-2-Aminoethylcyclanols”,Synthetic Communications, vol. 28, No. 12, (1998), pp. 2303-2309.
Leonard, Nelson J. et al., “Small Charged Rings. II. The Synthesis of Aziridinium Salts”,Journal of the American Chemical Society, vol. 84, (1962), pp. 4806-4813.
Picotin, Gerard et al., “Activation of Zinc by Trimethylchlorosilane: An Improved Procedure for the Preparation of β-Hydroxy Esters from Ethyl Bromoacetate and Aldehydes or Ketones (Reformatsky Reaction)”,Journal of Organic Chemistry, vol. 52, (1987), pp. 4796-4798.
Whitehead, Calvert W. et al., “Diuretics. IV. 6-Chloro-3-substituted 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-Dioxides”,Journal of Organic Chemistry, vol. 26, (1961), pp. 2809-2813.
STN International, File REGISTRY, Registry Copyright Jul. 14, 2006 ACS on STN RN: 892733-99-2, 1 page.
STN International, File REGISTRY, Registry Copyright Aug. 8, 2006 ACS on STN RN: 899526-58-0, 1 page.

Affiliated with

Also associated with

Rating

P2X 7 receptor antagonists and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P2X 7 receptor antagonists and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P2X 7 receptor antagonists and their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4018570